Promisingly, several antagonists (e.g., FTY720, OP449, and EMQA) that target the SET–PP2A interface have been shown to inhibit tumor growth and overcome therapeutic resistance in various preclinical models10,11,20. This evidence concerns the gene SET and neoplasm.